Chapter Clinical Summary
Academic synthesis, diagnostic methodology, and surgical recommendationsSpinal instability associated with neoplastic disease is a biomechanical failure distinct from the biological presence of a tumor. Neoplastic osteolysis destroys vertebral bodies, pedicles, facet joints, and posterior ligamentous structures, progressively compromising the spine's capacity to support physiological loads without pain, deformity, or neurological deficit. Movement-related mechanical pain is often the earliest clinical manifestation, preceding pathological fractures, kyphotic collapse, or spinal cord compression. The core clinical imperative is recognizing that oncological tumor control and mechanical stability represent two distinct problems: radiation therapy can destroy tumor cells and relieve biological pain, but will not restore structural integrity to an unstable, collapsing spine. The chapter traces the development of neoplastic stability criteria up to the Spinal Instability Neoplastic Score (SINS), integrating clinical pain and multi-modality imaging into management pathways spanning radiotherapy, cement augmentation, minimally invasive stabilization, and open decompression.
To understand the biomechanical mechanisms of tumor-induced spinal instability, recognize pathognomonic clinical and radiographic signs, apply the SINS classification to standardize multidisciplinary assessment, and guide decision-making among conservative observation, stereotactic radiotherapy, percutaneous augmentation, and surgical stabilization.
Tumor destruction alters vertebral stiffness and load distribution. Osteolytic lesions, pathological collapse, and posterior element involvement create mechanical failure. Movement-related mechanical pain worsens with upright posture and axial loading and improves with lying supine, differing fundamentally from constant, nocturnal biological tumor pain.
MRI evaluates tumor extent, thecal sac compression, and bone marrow infiltration. CT provides high-resolution visualization of cortical bone destruction, pedicle osteolysis, and fracture lines. Plain radiographs assess overall spinal alignment and progressive kyphosis. These modalities are complementary.
The Spinal Instability Neoplastic Score (SINS) integrates six variables: anatomical location, pain character, bone lesion quality (lytic vs blastic), spinal alignment, vertebral body collapse, and posterolateral element involvement. SINS categorizes the spine into stable (0-6), potentially unstable (7-12), and unstable (13-18). Figures 52.1 to 52.3 show how similar-appearing lesions have different stability profiles.
Stable spines (SINS 0-6) are managed oncologically (radiotherapy, systemic therapy). Potentially unstable spines (SINS 7-12) warrant surgical oncology consultation. Unstable spines (SINS 13-18) require surgical stabilization. Decompression is added if epidural cord compression exists. Vertebroplasty/kyphoplasty provide focal anterior support in select cases, but cannot replace posterior instrumentation in gross three-column instability.
Conventional radiotherapy and Stereotactic Body Radiotherapy (SBRT) target local tumor cells, while surgery stabilizes mechanical failure and decompresses neural tissue. Modern hybrid protocols integrate separation surgery followed by SBRT.
In clinical practice, when evaluating a cancer patient with spine pain, the clinician must ask: 'Is there tumor?' and 'Is the spine mechanically stable?' Movement-provoked mechanical pain relieved by lying flat strongly indicates instability. Applying the SINS criteria provides a universal language between oncologists, radiation oncologists, and spine surgeons. Patients with SINS scores of 7-12 (potentially unstable) or 13-18 (unstable) must be evaluated by a spine surgeon before starting radiation, because radiating an unstable collapsing spine often leads to progressive kyphosis, hardware failure, and acute spinal cord compression. Minimally invasive percutaneous pedicle screw fixation with or without cement augmentation achieves rapid mechanical stabilization and pain relief with minimal blood loss and swift return to systemic oncological treatments.